Deltex Instruments purchased Doptek in 1989. The two companies ran in parallel until 1st October 1992, when Deltex Medical was officially incorporated. The development of ODM1 was directly led by the MD thesis of Dr Mervyn Singer (now Professor of Intensive Care Medicine at University College Hospital, London) entitled “Continuous Haemodynamic Monitoring by Oesophageal Doppler”.
Developments in the Oesophageal Doppler led to the release of the ODM2 in 1995. This was subsequently followed by upgraded technology in the form of CardioQ (1999) and the CardioQ-ODM (2008). The CardioQ-ODM+, the world’s first fluid management system incorporating both ODM and PPWA technologies, was released in 2012.
In 2001, Deltex Medical passed the £1million turnover mark with sales of £1.3million. Deltex was floated on the AIM market in November 2001.
ODM technology has since received a number of awards and recommendations. These include the NICE MTG3 Guidelines, published in 2011, being named as one of six High Impact Innovations in Innovation, Health and Wealth (2011) as well as a recommendation by the Enhanced Recovery Partnership (2012).
- Deltex Instruments founded by Pauline Thomas. Primary product is the Flexiflo enteral feeding pump manufactured in Portsmouth and distributed by Abbott Laboratories.
- Deltex Instruments purchased Doptek, designer and manufacturer of Doppler ultrasound devices in Chichester.Dr Mervyn Singer completed his MD thesis “Continuous Haemodynamic Monitoring by Oesophageal Monitoring”.
- ODM1 released in the UK.
- First Randomised Control Trial showing the benefit of using ODM in cardiac surgery published by Mythen and Webb.
- ODM2 released, marketed by Abbott Laboratories.
- Formation of Deltex Medical Inc. in Texas, USA.
- Launch of CardioQ.
- Formation of Deltex Sales and Marketing Operations in the UK.
- Death of Deltex Instruments founder, Pauline Thomas.
- Deltex Medical listed on NASDAQ.
- Company sales passed the £1million turnover point with total sales of £1.3million.
- Deltex Medical was floated on the AIM market. This was originally planned for 11th September 2001, but was delayed until November due to the events of 9/11.
- University College Hospital, London, announced their Enhanced Surgical Treatment and Recovery Program (ESTReP), including the use of CardioQ as a standard of Care.
- CardioQ-ODM was launched.
- National Technology Adoption Centre (NTAC) “Howtowhyto” Guide published.
- NICE Guideline on ODM(MTG3) published, recommending the use of ODM for all patients undergoing major or high risk surgery.
- “Innovation, Health and Wealth – Accelerating Adoption in the NHS” was published, naming ODM as one of six High Impact Innovations.
- NTAC’s IOFM Adoption Pack released.
- CQUIN 2013/14 Guidance published, naming ODM as one of six High Impact Innovations.
- Enhanced Recovery Program – Fulfilling the Potential, published.